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The beneﬁ ts and harms of intravenous thrombolysis with 
recombinant tissue plasminogen activator within 6 h of 
acute ischaemic stroke (the third international stroke trial 
[IST-3]): a randomised controlled trial
The IST-3 collaborative group*
Summary
Background Thrombolysis is of net beneﬁ t in patients with acute ischaemic stroke, who are younger than 80 years of 
age and are treated within 4·5 h of onset. The third International Stroke Trial (IST-3) sought to determine whether a 
wider range of patients might beneﬁ t up to 6 h from stroke onset.
Methods In this international, multicentre, randomised, open-treatment trial, patients were allocated to 0·9 mg/kg 
intravenous recombinant tissue plasminogen activator (rt-PA) or to control. The primary analysis was of the 
proportion of patients alive and independent, as deﬁ ned by an Oxford Handicap Score (OHS) of 0–2 at 6 months. 
The study is registered, ISRCTN25765518.
Findings 3035 patients were enrolled by 156 hospitals in 12 countries. All of these patients were included in the 
analyses (1515 in the rt-PA group vs 1520 in the control group), of whom 1617 (53%) were older than 80 years of age. 
At 6 months, 554 (37%) patients in the rt-PA group versus 534 (35%) in the control group were alive and independent 
(OHS 0–2; adjusted odds ratio [OR] 1·13, 95% CI 0·95–1·35, p=0·181; a non-signiﬁ cant absolute increase of 14/1000, 
95% CI –20 to 48). An ordinal analysis showed a signiﬁ cant shift in OHS scores; common OR 1·27 (95% CI 1·10–1·47, 
p=0·001). Fatal or non-fatal symptomatic intracranial haemorrhage within 7 days occurred in 104 (7%) patients in the 
rt-PA group versus 16 (1%) in the control group (adjusted OR 6·94, 95% CI 4·07–11·8; absolute excess 58/1000, 
95% CI 44–72). More deaths occurred within 7 days in the rt-PA group (163 [11%]) than in the control group (107 [7%], 
adjusted OR 1·60, 95% CI 1·22–2·08, p=0·001; absolute increase 37/1000, 95% CI 17–57), but between 7 days and 
6 months there were fewer deaths in the rt-PA group than in the control group, so that by 6 months, similar numbers, 
in total, had died (408 [27%] in the rt-PA group vs 407 [27%] in the control group).
Interpretation For the types of patient recruited in IST-3, despite the early hazards, thrombolysis within 6 h improved 
functional outcome. Beneﬁ t did not seem to be diminished in elderly patients.
Funding UK Medical Research Council, Health Foundation UK, Stroke Association UK, Research Council of Norway, 
Arbetsmarknadens Partners Forsakringsbolag (AFA) Insurances Sweden, Swedish Heart Lung Fund, The Foundation 
of Marianne and Marcus Wallenberg, Polish Ministry of Science and Education, the Australian Heart Foundation, 
Australian National Health and Medical Research Council (NHMRC), Swiss National Research Foundation, 
Swiss Heart Foundation, Assessorato alla Sanita, Regione dell’Umbria, Italy, and Danube University.
Introduction
Each year, about 22 million people have a stroke world-
wide,1,2 of whom 4 million reside in high-income 
countries,3,4 where thrombolytic therapy is aﬀ ordable 
and feasible. The burden of ischaemic stroke among 
the elderly is large and increasing;2,5 and we estimate 
that annually ischaemic stroke aﬀ ects about a million 
people older than 80 years of age in high-income 
countries and about 3 million in low-income and 
middle-income countries.
Thrombolytic therapy with intravenous recombinant 
tissue plasminogen activator (rt-PA), when approved in 
Europe, was restricted to the treatment of patients 
younger than 80 years of age with acute ischaemic stroke 
who could be treated within 3 h. A Cochrane systematic 
review of the 11 completed trials of thrombolysis 
(including 3977 patients) with intravenous rt-PA for 
acute ischaemic stroke showed that treatment was 
associated with a signiﬁ cant increase in survival free of 
disability, despite an early 3% excess of fatal intracranial 
haemorrhage.6 The review also suggested that treatment 
might be beneﬁ cial up to 6 h.6 An individual patient data 
meta-analysis of a subset of intravenous rt-PA trials 
further showed that the earlier treatment was given, the 
greater the chance of a favourable outcome.7 Older 
people have been under-represented in stroke trials in 
general,8 and in stroke thrombolysis trials in particular 
(only 79 people aged older than 80 years had been 
included in trials of rt-PA).6 As a result of the current 
European Union (EU) approval criteria, treatment is 
only applicable to a small proportion of patients with 
acute stroke.9
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The Third International Stroke Trial (IST-3), therefore, 
had the following objectives: to establish the balance of 
beneﬁ ts and harms of thrombolytic therapy with rt-PA in 
patients who did not exactly meet the licence criteria 
(especially elderly patients); determine whether a wider 
range of patients might beneﬁ t from this treatment; 
assess which categories of patients were most likely to 
beneﬁ t by investigating possible interactions between 
treatment eﬀ ect and various factors (including age, stroke 
severity, and early brain imaging results); reﬁ ne current 
estimates of the duration of the therapeutic time window; 
and to improve the external validity and precision of the 
existing estimates of the overall treat ment eﬀ ects (beneﬁ ts 
and harms). The primary trial hypothesis was that 
0·9 mg/kg rt-PA (maximum 90 mg) given to adult 
patients of all ages with acute ischaemic stroke, within 
6 h of symptom onset, increased the proportion of people 
who were alive and independent at 6 months.
Methods
Study design and patients
IST-3 was a pragmatic10 international, multicentre, 
randomised-controlled, open-treatment trial. The initial 
pilot phase was double-blinded and placebo-controlled. 
At the end of the pilot phase, since the main phase 
compared treatment with open control, several additional 
measures were introduced to minimise bias in the 
assessment of early and late outcomes.11 We have 
published reports of the rationale for the trial,12 the 
protocol,13 an update on recruitment, amendments to the 
protocol and the baseline characteristics of the patients 
recruited,11 and the statistical analysis plan.14
The eligibility criteria can be summarised in terms of the 
uncertainty principle.15–17 Inclusion and exclusion criteria 
are listed in detail in the protocol.13 Brieﬂ y, patients were 
eligible according to the following criteria: they had symp-
toms and signs of clinically deﬁ nite acute stroke; the time 
of stroke onset was known; treatment could be started 
within 6 h of onset; and CT or MRI had reliably excluded 
both intracranial haemorrhage and structural brain le-
sions, which could mimic stroke (eg, cerebral tumour). 
Additionally, if the patient had a clear indication for in-
travenous thrombolysis with rt-PA, they were to be treated 
in accordance with local guidelines. Equally, if the patient 
had a clear contraindication to treatment they were not to 
be entered in the trial. Only if both the clinician and the 
patient (or a relevant proxy for the patient) felt that the 
treatment was promising but unproven, could the patient 
be included in the trial after appropriate informed consent 
from the patient or a valid proxy. The protocol was approved 
by the Multi centre Research Ethics Committees, Scotland 
(re ference MREC/99/0/78), and by local ethical committees.
This study is registered, ISRCTN25765518.
Procedures
Clinicians entered baseline data via a telephone voice-
activated or a secure web-based randomisation system. 
After the system had recorded and checked the data, 
patients were allocated either immediate thrombolysis 
with 0·9 mg/kg of intravenous rt-PA to a maximum of 
90 mg (10% bolus with the remainder over 1 h) or control 
treatment. The system would not accept patients with 
blood pressure or glucose levels outside protocol-deﬁ ned 
criteria (appendix pp 4–5) or other data inconsistencies. 
The system used a minimisation algorithm to achieve 
optimum balance for key prognostic factors (table 1), 
and from January, 2006, minimisation was additionally 
stratiﬁ ed by world region and then minimised on all the 
other key factors within regions.
To be eligible to join the trial, participating hospitals 
had to have an organised system of stroke care. Acute-
care protocols were not speciﬁ ed by the trial, but had to 
include the components of eﬀ ective stroke-unit care,19 
including, soon after admission, intravenous access, 
monitoring of physiological variables, correction of any 
abnormalities, and where clinically appropriate, intra-
venous-ﬂ uid therapy. All patients in the trial were to be 
treated within that organised system of stroke care, 
irrespective of treatment allocation. Patients allocated to 
the control group were to avoid treatment with rt-PA and 
received stroke care in the same clinical environment 
as those allocated to the rt-PA group. Both treatment 
groups had blood pressure monitored closely over the 
ﬁ rst 24 h. In the double-blinded phase, both groups were 
to avoid antiplatelet or anticoagulant therapy for 24 h. In 
the open phase, patients allocated to the control group 
were to start aspirin immediately. Blood pressure was 
managed in the same way in both treatment groups, 
according to local protocol. Additionally, all centres were 
asked for their pretrial experience of thrombolysis for 
treatment of stroke, and if the centre had, before joining 
the trial, a protocol for open-label use of rt-PA and had 
treated at least three people in the 12 months before 
joining the trial, the centre was classed as experienced.
All patients had a CT or MRI brain scan before 
randomisation and a follow-up scan at 24–48 h. A repeat 
brain scan was required if the patient deteriorated neuro-
logically or intracranial haemorrhage was suspected for 
any reason. Although CT scanning was preferred, MRI 
was allowed. All scans were sent to the trial centre in 
Edinburgh for masked central rating of any signs of 
visible early ischaemia (presence and extent of hypo-
attenuation, swelling, hyperattenuated artery), haemor-
rhage, and background brain changes (leukoaraiosis, 
atrophy, prior stroke lesions, non-stroke lesions) with 
validated rating methods.20–25 Images were assessed with 
all original identiﬁ ers stripped from the record, and then 
viewed via a secure web-based image viewing system 
by an international panel of expert radiologists. All 
assessments were made masked to all patient details and 
treatment allocation.
The primary outcome speciﬁ ed in version 1·93 of the 
protocol and in the published statistical analysis plan14 
was the proportion of patients alive and independent as 
For the study protocol see 
http://www.ist3.com
See Online for appendix
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measured by the Oxford Handicap Score (OHS),26 a 
commonly used variant of the modiﬁ ed Rankin score.27 
Patients with an OHS of 0, 1, or 2 were classed as 
independent. The statistical analysis plan speciﬁ ed an 
ordinal analysis of the OHS score at 6 months. Additional 
secondary outcomes were to be reported separately.
Events occurring within 7 days of stroke were recorded 
by the local trial clinician on the 7-day form: deaths 
subdivided by cause (swelling of the initial infarct, 
intracranial haemorrhage, other deaths from the initial 
stroke, recurrent ischaemic stroke, recurrent stroke of 
unknown type, any other cause); symptomatic intra-
cranial haemorrhage; recurrent ischaemic stroke; recur-
rent stroke of unknown type; neurological deterioration 
attributed to swelling of the initial ischaemic stroke; 
neurological deterioration not attributable to swelling of 
the initial ischaemic stroke or haemorrhage; and major 
extracranial haemorrhage (operational deﬁ nitions of 
rt-PA (n=1515) Control 
(n=1520)
Baseline variables collected before treatment allocation*
Region†
Northwest Europe (UK, Austria, 
Belgium, Switzerland)
792 (52%) 797 (52%)
Scandinavia (Norway, Sweden) 251 (17%) 250 (16%)
Australasia 89 (6%) 90 (6%)
Southern Europe (Italy, Portugal) 204 (13%) 204 (13%)
Eastern Europe (Poland) 174 (11%) 173 (11%)
Americas (Canada, Mexico) 5 (<1%) 6 (<1%)
Age (years)†
18–50 59 (4%) 68 (4%)
51–60 98 (6%) 104 (7%)
61–70 188 (12%) 177 (12%)
71–80 353 (23%) 371 (24%)
81–90 706 (47%) 701 (46%)
>90 111 (7%) 99 (7%)
Sex†
Female 782 (52%) 788 (52%)
NIHSS†
0–5 304 (20%) 308 (20%)
6–10 422 (28%) 430 (28%)
11–15 306 (20%) 295 (19%)
16–20 270 (18%) 273 (18%)
>20 213 (14%) 214 (14%)
Delay in randomisation†‡
0–3·0 h 431 (28%) 418 (28%)
3·0–4·5 h 577 (38%) 600 (39%)
4·5–6·0 h 507 (33%) 500 (33%)
>6·0 h 0 (0%) 2 (<1%)
Atrial ﬁ brillation 473 (31%) 441 (29%)
Systolic blood pressure
≤143 mm Hg 487 (32%) 492 (32%)
144–164 mm Hg 498 (33%) 518 (34%)
≥165 mm Hg 530 (35%) 510 (34%)
Diastolic blood pressure§
≤74 mm Hg 462 (31%) 445 (29%)
75–89 mm Hg 541 (36%) 588 (39%)
≥90 mm Hg 500 (33%) 480 (32%)
Blood glucose¶
≤5 mmol/L 254 (18%) 285 (21%)
6–7 mmol/L 664 (48%) 638 (46%)
≥8 mmol/L 455 (33%) 456 (33%)
(Continues in next column)
rt-PA (n=1515) Control 
(n=1520)
(Continued from previous column)
Treatment with antiplatelet drugs in 
previous 48 h†
775 (51%) 787 (52%)
Predicted probability of poor outcome at 6 months||
<40% 351 (23%) 378 (25%)
40–50% 169 (11%) 160 (11%)
50–75% 361 (24%) 357 (23%)
≥75% 634 (42%) 625 (41%)
Stroke clinical syndrome†**
TACI 639 (42%) 666 (44%)
PACI 596 (39%) 551 (36%)
LACI 168 (11%) 164 (11%)
POCI 110 (7%) 136 (9%)
Other 2 (<1%) 3 (<1%)
Baseline variables collected from prerandomisation scan
Expert reader’s assessment of acute 
ischaemic change††
·· ··
Scan completely normal 140 (9%) 129 (8%)
Scan not normal but no sign of 
acute ischaemic change
743 (49%) 781 (51%)
Signs of acute ischaemic change 624 (41%) 600 (40%)
Data are number (%). Percentages exclude missing values from denominators. 
rt-PA=recombinant tissue plasminogen activator. NIHSS=National Institutes of 
Health Stroke Scale. TACI=total anterior circulation infarct. PACI=partial anterior 
circulation infarct. LACI=lacunar infarct. POCI=posterior circulation infarct. *Data 
for these variables were gathered via the web-based or telephone randomisation 
system and had to be entered, complete, and have passed range and consistency 
checks before the system would issue a treatment allocation. †Variables were used 
in the minimisation algorithm. ‡Two patients in the control group were randomly 
assigned at more than 6 h (protocol violation). One of these was recorded as 
having severe swelling on the randomisation scan, because the stroke had in fact 
occurred about 24 h earlier. §Diastolic blood pressure missing for 12 patients in the 
rt-PA group and seven in the control group. ¶For the ﬁ rst 282 patients, glucose 
levels were not recorded. After patient 282, glucose levels were measured at 
randomisation. One further patient had a missing value. ||Risk predicted by novel 
model designed by Konig and colleagues.18 This model predicts outcome (death or 
Bartel Index <95) at 3 months. If we assume that those who die between 3 months 
and 6 months were dependent at 3 months, and those who do not die between 
3 months and 6 months do not change their dependency status, then the risk 
estimates are likely to be quite accurate for death or dependency at 6 months. 
**Stroke clinical syndrome derived from baseline clinical features assigned by an 
algorithm (algorithm available on request). For the randomisation algorithm TACI, 
PACI, and POCI were combined as non-lacunar so the process ensured balance in 
the number of lacunar syndromes in each treatment group. ††Expert panel’s 
masked assessment of prerandomisation scan. This assessment was done by 
members of the expert panel after randomisation and masked to treatment 
allocation and all clinical details. Prerandomisation scans were unavailable for 
eight patients in the rt-PA group and ten in the control group.
Table 1: Baseline characteristics
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each of these events are provided in the published 
protocol13 and statistical analysis plan14). Other fatal and 
non-fatal non-cerebral events were also recorded and 
coded. Data on potential reports of any of these events 
were extracted from the trial database and presented to 
the adjudication committee who were masked to 
treatment allocation.
Randomisation and masking
To avoid predictable alternation of treatment allocation, 
and thus potential loss of allocation concealment, 
patients were allocated with a probability of 0·80 to the 
treatment group that would minimise the diﬀ erence 
between the groups on the key prognostic factors. 
Additional details of the procedures used in the double-
blinded phase of the study are reported elsewhere.11 The 
randomisation system informed local clinicians of the 
patients’ unique trial identiﬁ cation number, and the 
weight-adjusted dose of drug or placebo in the double-
blinded phase, or of the weight-adjusted drug dose 
among those allocated thrombolysis in the open phase, 
to be given as a 10% bolus with the remainder by an 
infusion over 1 h. 
With the exception of the 276 patients treated in the 
double-blinded phase of the trial, treatment was given 
openly and neither the patient nor the treating clinicians 
were masked. Hospital staﬀ  completed an early outcome 
form at 7 days, death, or hospital discharge, whichever 
occured ﬁ rst, recording details of events occurring in 
hospital within 7 days, details of background treatments 
given and functional status. 6 months after random-
isation, general practitioners (or hospital coordinators) 
were contacted by the IST-3 trial oﬃ  ce staﬀ  to check that 
the patient was alive and inform them that they might be 
approached for follow-up. If appropriate, the IST-3 trial 
oﬃ  ce masked staﬀ  then mailed a postal questionnaire to 
patients to assess outcome. Non-responders were con-
tacted by telephone, and follow-up data was obtained by 
telephone interview. In Italy and Austria, all follow-ups 
were done as telephone interviews by a clinician, who 
was masked to treatment allocation and was highly 
experienced in outcome assessment. In Portugal, 
patients were followed up in clinic by clinicians not 
involved in the patients’ initial treatment, again, masked 
to treatment allocation as far as possible. To assess the 
durability of any treatment beneﬁ t beyond 6 months, 
patients recruited in the UK (and in other countries 
where appropriate funding had been obtained) were also 
followed up at 18 months. All follow-up done by patient 
contact for these analyses ceased on March 31, 2012, but 
recording of deaths from national registries of deaths 
continues in UK, Norway, and Sweden.
Statistical analysis
At the outset of the trial in 2000, we estimated that, 
among the type of patients likely to be recruited at the 
time, to detect both an absolute diﬀ erence of 10% in the 
proportion of patients alive and independent at 6 months 
after treatment and to have suﬃ  cient power to permit 
reliable analyses of the prespeciﬁ ed subgroups, a sample 
of 6000 patients would be needed. A trial of that size 
could detect a clinically worthwhile net beneﬁ t of as little 
as 3% absolute diﬀ erence in the primary outcome (80% 
power, α=0·05). However, it was clear by 2007 that 
obtaining a sample of 6000 was no longer feasible, and 
the Steering Committee agreed a revised recruitment 
target.11 The sample size, re-estimated in 2007 on the 
basis of event rates in both treatment groups combined, 
was 3100. This sample size gave 80% power to detect an 
absolute diﬀ erence of 4·7% in the primary outcome.11
We monitored the quality and integrity of the 
accumulating clinical data according to a protocol 
agreed with the study sponsors, which involved central 
statistical monitoring according to the principles 
described by Buyse and colleagues,28 supplemented by 
onsite monitoring and detailed source data veriﬁ cation in 
a random sample of 10% of records in centres that had 
recruited more than 30 patients, or when patterns in the 
data at a centre seemed anomalous. All IST-3 monitoring 
procedures were compliant with requirements of all 
study sponsors, the national ethics committees and 
regulatory agencies in the 12 participating countries, and 
they met all appropriate regulatory and Good Clinical 
Practice requirements. All baseline data, 7-day, and 
6-month outcome data were subject to veriﬁ cation checks 
built into the randomisation and data management 
system. We monitored all baseline and postrandomisation 
imaging, which provided additional cross-checks on 
recruited patients and centre per formance. An expert 
radiologist checked all scans, masked to clinical details 
and treatment allocation, immediately on receipt at the 
trial oﬃ  ce, for evidence of adverse events and protocol 
deviations. The independent data monitoring committee 
met at least annually to review the unmasked data on 
major outcome events in the trial, on the background 
stroke-unit care received by trial patients (to ensure it 
was equal in both treatment groups), relevant external 
data (including updates of the Cochrane systematic 
review and reports from large-scale registries of rt-PA 
use) in strict conﬁ dence throughout the course of the 
trial. The committee judged these data never met the 
protocol-speciﬁ ed criteria to recommend modiﬁ cation of 
the protocol or halt recruitment to the study.
The statistical analysis plan was published14 before 
unmasking of the authors to the data. All randomly 
assigned patients were included in the analysis. Masked 
analysis of the patients’ baseline characteristics showed 
clear diﬀ erences in key prognostic factors (age, stroke 
severity, degree of ischaemic change on baseline CT or 
MRI) in patients randomly assigned at diﬀ erent times 
after stroke onset, which might complicate the estimation 
of the eﬀ ect of treatment overall and in subgroups.11 
Therefore, the primary analysis of the eﬀ ect of treatment 
on the primary outcome was adjusted by logistic regression 
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for linear eﬀ ects for the following covariates: age; National 
Institutes of Health stroke scale (NIHSS) score; time from 
onset of stroke symptoms to randomisation; and presence 
(vs absence) of ischaemic change on the prerandomisation 
brain scan according to expert assessment. An unadjusted 
analysis is also presented.
The trial did not meet its original target of 6000 patients, 
and so was no longer adequately powered to detect a 3% 
absolute diﬀ erence in the primary outcome (with 80% 
power and α=0·05). The statistical-analysis-plan writing 
committee, which did not have access to the accumulating 
data, was therefore expanded to include an independent 
statistician (Gordon Murray, University of Edinburgh, 
Edinburgh, UK) to advise on the correct approach. The 
writing group was persuaded by the recent empirical 
evidence that the ordinal method was both statistically 
more eﬃ  cient (eﬀ ectively reducing the sample size 
required in stroke trials29) and robust against substantial 
deviations from the proportional assumption.30 We 
therefore speciﬁ ed in the statistical analysis plan an 
ordinal logistic regression analysis, as a secondary 
outcome, in which the OHS as a dependent variable had 
5 levels: levels 4, 5, and 6 were combined into a single 
level and levels 0, 1, 2, 3 were retained as distinct.
In this model the treatment odds ratios between one 
level and the next were assumed to be constant, so a 
single parameter summarises the shift in outcome 
distribution between treatment and control groups. For 
patients known to be alive at 6 months, but with an 
unknown OHS, we used the level of function recorded 
on the 7-day form (ie, measured at 7 days or before 
discharge from hospital) to impute 6-month functional 
status.14 We chose this simple form of imputation because 
it eﬀ ectively classiﬁ ed 6-month outcomes in patients for 
whom both 7-day and 6-month data were known (data 
not shown). Analyses were done with SAS (version 9.2).
Role of the funding source
The sponsors of the study had no role in design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Between May, 2000, and July, 2011, 3035 patients were 
enrolled in 156 centres in 12 countries. Baseline 
characteristics were well balanced between treatment 
groups (ﬁ gure 1, table 1). 1617 (53%) patients were older 
than 80 years of age. Vital status at 6 months was known 
for 99% (3011 of 3035) of patients. Overall, 2581 (95%) of 
2714 patients with data (data for some relevant variables 
were not collected in the initial phase) did not meet the 
prevailing EU-licence-approval criteria. Additional base-
line characteristics are shown in appendix pp 2–3.
Of those assigned to the rt-PA group, 26 (2%) did not 
receive any rt-PA treatment, and of those assigned to the 
control group, seven (<1%) received at least some rt-PA. 
Among patients allocated to the rt-PA group, the mean 
time from randomisation to injection of the bolus was 
18 min, the mean time from onset to treatment was 4·2 h 
(SD 1·2), median 4·2 h (IQR 3·2–5·2). Appendix pp 2–3 
documents devi ations from the protocol and the 
background treatments that were given during the ﬁ rst 
7 days. Most patients were cared for in a stroke unit, and 
there was no evidence of a major imbalance in the use of 
background treat ments or place of care (admissions 
ward, or stroke unit) over the ﬁ rst 7 days; an analysis of 
blood pressure in patients measured after randomisation 
showed no signiﬁ cant diﬀ erence at each timepoint over 
the ﬁ rst 24 h in either systolic or diastolic blood pressures 
between the two treatment groups. However, the 
proportion of those who had spent at least 1 day in a 
high-dependency area was somewhat higher among 
patients assigned to the rt-PA group than in the control 
group (328 [24%] vs 237 [17%]), though in both groups, 
the median stay in such an area was just 1 day. 76 (49%) 
centres were classed as experienced in treating stroke 
with thromb olysis, and 1143 patients were recruited by 
these centres.
Patients recruited within 1–2 h of onset were sig-
niﬁ cantly more likely to have a more severe neurological 
deﬁ cit did than those recruited at later timepoints after 
onset (test for linear trend p<0·0001). Similarly, patients 
Figure 1: Trial proﬁ le
rt-PA=recombinant tissue plasminogen activator. OHS=Oxford Handicap Score. 
*Of the patients allocated to control, seven actually received some rt-PA. 
Appendix pp 4–5 gives more detail of treatment actually received and 
background care.
3035 enrolled
3035 randomly assigned
1515 assigned to the rt-PA group
1488 received at least
some rt-PA
26 did not receive
any rt-PA
1 treatment received
unknown
1520 assigned to control group
1508 received allocated
intervention
7 did not receive
allocated intervention*
5 treatment received
unknown
1515 assessed at 7 days
1352 alive at 7 days
163 died within 7 days
1520 assessed at 7 days
1413 alive at 7 days
107 died within 7 days
1515 assessed at 6 months
1065 alive (OHS known)
31 alive (OHS not known)
11 not known to be dead
(OHS not known)
408 dead before 6 months
1520 assessed at 6 months
1059 alive (OHS known)
41 alive (OHS not known)
13 not known to be dead
(OHS not known)
407 dead before 6 months
1515 analysed 1520 analysed
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recruited at earlier time points were signiﬁ cantly older 
than those recruited later (test for linear trend p<0·0001). 
The proportion of patients with a deﬁ nitely visible 
ischaemic lesion (vs only possible or no early ischaemic 
change) on baseline imaging rose with time (test for 
linear trend p=0·0045).
At 6 months, 554 (37%) in the rt-PA group versus 
534 (35%) in the control group were alive and 
independent in activities of daily living (OHS 0–2; 
table 2). A secondary ordinal analysis provided evidence 
of a favourable shift in the distribution of OHS scores at 
6 months with treatment (p<0·001; ﬁ gure 2). More 
patients died within 7 days in the rt-PA group than in the 
control group, but between 7 days and 6 months there 
were correspondingly fewer deaths in the rt-PA group.
Symptomatic intracranial haemor rhage and fatal or 
non-fatal deterioration due to swelling of the infarct 
within 7 days occurred in more patients in the rt-PA 
group than in the control group (table 3). rt-PA was 
associated with a signiﬁ cant increase in extracranial 
haemorrhages (table 3).
To assess the eﬀ ect of treatment on the primary 
outcome, the statistical analysis plan predeﬁ ned a small 
subset of key prognostic subgroups (ﬁ gure 3). The 
subgroup analyses are of the adjusted eﬀ ects and take 
account of the fact that, for a speciﬁ c prognostic factor, 
the distribution of other factors might diﬀ er between 
subcategories. For example, in older patients the time to 
randomisation was shorter. The subgroup analyses for a 
speciﬁ c factor provide estimated eﬀ ects within sub-
categories that adjust for such imbalances. Overall, little 
variation occurred in the adjusted eﬀ ects of treatment in 
diﬀ erent subgroups. However, a signiﬁ cant diﬀ erence 
rt-PA 
(n=1515)
Control 
(n=1520)
Adjusted analysis* Unadjusted analysis†
Odds ratio (95% CI) p value Odds ratio (95% CI) p value Absolute 
diﬀ erence per 
1000 (95% CI)‡
Died within 7 days 163 (11%) 107 (7%) 1·60 (1·22 to 2·08) 0·001 1·59 (1·23 to 2·07) 0·0004 37 (17 to 57)
Died between 7 days and 6 months 245 (16%) 300 (20%) 0·73 (0·59 to 0·89) 0·002 0·78 (0·65 to 0·95) 0·011 –36 (–63 to –8)
Status at 6 months
Vital status unknown, disability imputed 11 13 ·· ·· ·· ·· ··
Alive at 6 months, disability imputed 31 41 ·· ·· ·· ·· ··
Known 6 month vital and disability status 1473 1466 ·· ·· ·· ·· ··
Number included in analysis (status 
known or imputed)
1515 1520 ·· ·· ·· ·· ··
OHS at 6 months§
0 138 (9%) 116 (8%) ·· ·· ·· ·· ··
1 225 (15%) 204 (13%) ·· ·· ·· ·· ··
2 191 (13%) 214 (14%) ·· ·· ·· ·· ··
3 235 (16%) 193 (13%) ·· ·· ·· ·· ··
4 115 (8%) 140 (9%) ·· ·· ·· ·· ··
5 203 (13%) 246 (16%) ·· ·· ·· ·· ··
Died before 6 months 408 (27%) 407 (27%) 0·96 (0·80 to 1·15) 0·672 1·01 (0·86 to1·19) 0·924 2 (–30 to 33)
Alive and favourable outcome (0+1) 363 (24%) 320 (21%) 1·26 (1·04 to 1·53) 0·018 1·18 (0·99 to 1·41) 0·055 29 (–1 to 59)
Alive and independent (0+1+2)¶ 554 (37%) 534 (35%) 1·13 (0·95 to 1·35) 0·181 1·06 (0·92 to1·24) 0·409 14 (–20 to 48)
Data are number (%) unless otherwise stated. rt-PA=recombinant tissue plasminogen activator. OHS=Oxford Handicap Scale. *Odds ratios and p values were calculated by 
logistic regression after adjusting for age (linear), National Institutes of Health Stroke Scale (linear), time (linear), and presence or absence of visible acute ischaemic change 
on baseline scan as judged by the expert reader. †p value calculated from test of diﬀ erence between percentages for rt-PA and control, using normal approximation. 
‡Absolute diﬀ erence calculated as rt-PA – control, so a positive number indicates this outcome was more frequent in the treatment group. §OHS: 0, no symptoms at all; 
1, symptoms, but these do not interfere with everyday life; 2, symptoms that have caused some changes in lifestyle but patients are still able to look after themselves; 3, symptoms 
that have signiﬁ cantly changed lifestyle and patients need some help looking after themselves; 4, severe symptoms requiring help from other people but not so bad as to need 
attention day and night; 5, severe handicap needing constant attention day and night. ¶Primary outcomes.
Table 2: Deaths by 6 months and functional outcome at 6 months
Figure 2: Outcome at 6 months: Oxford Handicap Scale (OHS) by 
treatment group
For the ordinal analysis, which was adjusted for age, National Institutes of 
Health Stroke Scale (NIHSS), delay (all linear), and and presence or absence of 
visible acute ischaemic change on baseline scan as judged by the expert reader, 
the statistical analysis plan prespeciﬁ ed that OHS levels 4, 5, and 6 were grouped 
and 0, 1, 2, 3 remained discrete. In that analysis, the common odds ratio was 
1·27 (95% CI 1·10–1·47; p=0·001). An ordinal analysis with OHS levels 0, 1, 2, 3, 
4, 5, and 6 all discrete, adjusted in the same way, gave an odds ratio of 1·17 
(95% CI 1·03–1·33; p=0·016). rt-PA=recombinant tissue plasminogen activator. 
0
8%
9% 15% 13% 16% 8% 13% 27%
13% 14% 13% 9% 16% 27%Control
rt-PA
1 2 3 4 5 6
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rt-PA 
(n=1515)
Control 
(n=1520*)
Adjusted analysis† Absolute diﬀ erence 
per 1000 (95% CI)‡
Odds ratio (95% CI) p value
Cerebral events
Symptomatic swelling of original infarct§
Non-fatal 21 (1%) 17 (1%) 1·23 (0·64 to 2·35) 0·539 3 (–5 to 11)
Fatal 47 (3%) 25 (2%) 1·89 (1·14 to 3·14) 0·013 15 (4 to 25)
Total 68 (4%) 42 (3%) 1·66 (1·11 to 2·49) 0·014 17 (4 to 31)
Symptomatic intracranial haemorrhage¶
Non-fatal 49 (3%) 9 (1%) 5·56 (2·72 to 11·4) <0·0001 26 (17 to 36)
Fatal 55 (4%) 7 (<1%) 8·12 (3·68 to 17·9) <0·0001 32 (22 to 42)
Total 104 (7%) 16 (1%) 6·94 (4·07 to 11·8) <0·0001 58 (44 to 72)
Neurological deterioration not due to swelling or haemorrhage
Non-fatal 107 (7%) 79 (5%) 1·37 (1·02 to 1·86) 0·038 19 (2 to 36)
Fatal 38 (3%) 49 (3%) 0·74 (0·48 to 1·14) 0·167 –7 (–19 to 5)
Total 145 (10%) 128 (8%) 1·14 (0·88 to 1·46) 0·320 11 (–9 to 32)
Recurrent ischaemic stroke
Non-fatal 18 (1%) 15 (1%) 1·21 (0·61 to 2·42) 0·583 2 (–5 to 9)
Fatal 3 (0%) 5 (<1%) 0·61 (0·14 to 2·57) 0·499 –1 (–5 to 2)
Total 21 (1%) 20 (1%) 1·06 (0·57 to 1·97) 0·846 1 (–8 to 9)
Recurrent stroke of unknown type
Non-fatal 1 (<1%) 2 (<1%) 0·50 (0·05 to 5·56) 0·574 –1 (–3 to 2)
Fatal 2 (<1%) 1 (<1%) 1·98 (0·18 to 22·3) 0·581 1 (–2 to 3)
Total 3 (<1%) 3 (<1%) 0·98 (0·20 to 4·89) 0·981 0 (–3 to 3)
Non-cerebral events||
Myocardial infarction
Non-fatal 18 (1%) 19 (1%) 0·89 (0·46 to 1·71) 0·717 –1 (–8 to 7)
Fatal 5 (<1%) 4 (<1%) 1·25 (0·33 to 4·68) 0·738 1 (–3 to 5)
Total 23 (2%) 23 (2%) 0·95 (0·53 to 1·71) 0·859 0 (–9 to 9)
Extracranial bleed
Non-fatal 14 (1%) 1 (<1%) 14·5 (1·90 to 110) 0·010 9 (4 to 14)
Fatal 2 (<1%) 2 (<1%) 0·99 (0·14 to 7·13) 0·995 0 (–3 to 3)
Total 16 (1%) 3 (<1%) 5·46 (1·59 to 18·8) 0·007 9 (3 to 14)
Allergic reaction
Non-fatal 12 (1%) 0 (0%) ·· ·· 8 (3 to 12)
Fatal 0 (0%) 0 (0%) ·· ·· 0 (0 to 0)
Total 12 (1%) 0 (0%) ·· ·· 8 (3 to 12)
Total deaths from cerebral causes within 7 days 145 (10%) 87 (6%) 1·76 (1·32 to 2·34) 0·0001 38 (20 to 57)
Total deaths from non-cerebral causes within 7 days** 18 (1%) 20 (1%) 0·89 (0·47 to 1·69) 0·717 –1 (–9 to 7)
Total deaths within 7 days 163 (11%) 107 (7%) 1·60 (1·22 to 2·08) 0·001 37 (17 to 57)
Data are number (%) unless otherwise stated. rt-PA=recombinant tissue plasminogen activator. *One patient in the control group was missing a 7-day form but did return 
a 6-month form, so was known to be alive at 7 days. This case has been omitted from the analysis. †Odds ratio and p value calculated from logistic regression after 
adjusting for age (linear), National Institutes of Health Stroke Scale (linear), time (linear), and presence or absence of visible acute ischaemic change on baseline scan. 
When no events occurred in one treatment group the logistic model was not applied. ‡Absolute diﬀ erence was calculated as rt-PA–control, so a positive number indicates 
this outcome was more frequent in the treatment group. §Symptomatic swelling of the original infarct was deﬁ ned as signiﬁ cant neurological deterioration accompanied 
by evidence of signiﬁ cant brain swelling as determined by the independent masked expert assessment of the scan deﬁ ned as: shift of the midline away from the side of 
the ventricle or eﬀ acement of the basal cisterns or uncal herniation on a postrandomisation scan (or autopsy if not rescanned before death). The presence of some degree 
of haemorrhagic transformation was permitted, provided it was not identiﬁ ed by the expert CT reader to be a major contributor to the mass eﬀ ect. ¶Symptomatic 
intracranial haemorrhage was deﬁ ned as signiﬁ cant neurological deterioration accompanied by clear evidence of signiﬁ cant intracranial haemorrhage on the 
postrandomisation scan (or autopsy if not rescanned and death occurs after 7 days). Signiﬁ cant haemorrhage was present on any postrandomisation scan if the expert 
reader both noted the presence of signiﬁ cant haemorrhagic transformation of the infarct or parenchymal haematoma and indicated that haemorrhage was a major 
component of the lesion (or was remote from the lesion and likely to have contributed signiﬁ cantly to the burden of brain damage). This event included clinical events 
described as a recurrent stroke within 7 days, in which the recurrent stroke was conﬁ rmed to be caused by an intracranial haemorrhage. ||Non-fatal cerebral events are 
exclusive. However, non-fatal non-cerebral events are not exclusive. A given patient could have one or more non-fatal non-cerebral events and a non-fatal cerebral event. 
**The deaths in the fatal rows are exclusive (a patient can only contribute to one of the fatal rows). Total deaths from non-cerebral causes include deaths not attributed to 
myocardial infarction, extracranial bleed, or allergic reaction.
Table 3: Fatal and non-fatal cerebral and non-cerebral events within 7 days of randomisation
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Figure 3: Adjusted eﬀ ect of treatment on the primary outcome (alive and independent, Oxford Handicap Score 0, 1, or 2) in subgroups
The key predeﬁ ned subgroups were age 80 years or younger, age older than 80 years, time from stroke onset to randomisation (0–3·0 h, 3·0–4·5 h, 4·5–6·0 h), initial 
stroke severity as measured by National Institutes of Health stroke score, and the appearance of the baseline brain scan on expert read for each subgroup (whether 
ischaemic change is visible or not). The treatment odds ratio in each subgroup has been adjusted for the linear eﬀ ects of the other key variables (age, NIHSS, and 
delay) but not for the presence or absence visible ischaemic change. It is for this reason that the adjusted odds ratio in the “Total” row at the bottom of the table does 
not exactly agree with the odds ratio in table 2. The choice of cut-points to deﬁ ne certain subgroups is slightly diﬀ erent to those given in table 1.14 On the graph, for 
each subgroup, the horizontal line represents the 99% CI, the diamond is centred on the overall estimate and it represents the 95% CI. The graph was generated with 
R (version 2.11.1). rt-PA=recombinant tissue plasminogen activator. NIHSS=National Institutes of Health Stroke Scale. TACI=total anterior circulation infarct. 
PACI=partial anterior circulation infarct. LACI=lacunar infarct. POCI=posterior circulation infarct.
Subgroup
rt-PA Control
Adjusted
p value
Events/number of patients
Age (years) 0·029
NIHSS score 0·003
Predicted probability of poor outcome at 6 months 0·009
Time to randomisation (h) 0·613
Acute ischaemic change on randomisation scan according to expert panel 0·534
Sex 0·409
Stroke syndrome 0·465
Clinician’s assessment of recent ischaemic change at randomisation 0·703
Atrial ﬁbrillation 0·574
Systolic blood pressure (mm Hg) 0·737
Diastolic blood pressure (mm Hg) 0·154
Glucose (mmol/L) 0·444
Treatment with antiplatelet drugs in previous 48 h 0·383
Trial phase 0·479
Centre with experience of thrombolysis 0·911
≤80
>80
0–5
6–14
15–24
≥25
<0·4
0·4–0·5
0·5–0·75
>0·75
0–3
3–4·5
>4·5
No
Yes
Female
Male
TACI
PACI
LACI
POCI
No evidence
Possible evidence
Deﬁnite evidence
No
Yes
≤143
144–164
≥165
≤74
75–89
≥90
≤5
6–7
≥8 143/455  (31·4%)
No
Yes
Blinded
Open
No
Yes
Total
331/698  (47·4%)
223/817  (27·3%)
221/304  (72·7%)
276/728  (37·9%)
 50/402  (12·4%)
  7/81   (8·6%)
256/351  (72·9%)
 88/169  (52·1%)
127/361  (35·2%)
 83/634  (13·1%)
132/431  (30·6%)
182/577  (31·5%)
240/507  (47·3%)
392/883  (44·4%)
158/624  (25·3%)
239/782  (30·6%)
315/733  (43·0%)
106/639  (16·6%)
281/596  (47·1%)
100/168  (59·5%)
 66/110  (60·0%)
381/894  (42·6%)
105/361  (29·1%)
 68/260  (26·2%)
440/1042 (42·2%)
114/473  (24·1%)
172/487  (35·3%)
196/498  (39·4%)
186/530  (35·1%)
151/462  (32·7%)
204/541  (37·7%)
193/500  (38·6%)
109/254  (42·9%)
261/664  (39·3%)
288/736  (39·1%)
265/775  (34·2%)
 34/136  (25·0%)
520/1379 (37·7%)
313/940  (33·3%)
241/575  (41·9%)
554/1515 (36·6%)
346/719  (48·1%)
188/799  (23·5%)
232/308  (75·3%)
268/724  (37·0%)
 33/421  (7·8%)
  1/65   (1·5%)
290/377  (76·9%)
 76/160  (47·5%)
118/357  (33·1%)
 50/624  (8·0%)
 95/418  (22·7%)
226/600  (37·7%)
213/500  (42·6%)
379/910  (41·6%)
149/598  (24·9%)
235/787  (29·9%)
299/731  (40·9%)
 96/665  (14·4%)
254/550  (46·2%)
103/164  (62·8%)
 79/136  (58·1%)
366/897  (40·8%)
108/340  (31·8%)
 60/281  (21·4%)
436/1078 (40·4%)
 98/440  (22·3%)
170/491  (34·6%)
196/518  (37·8%)
168/509  (33·0%)
133/445  (29·9%)
219/586  (37·4%)
178/480  (37·1%)
109/285  (38·2%)
242/636  (38·1%)
144/456  (31·6%)
282/725  (38·9%)
251/786  (31·9%)
 38/140  (27·1%)
496/1378 (36·0%)
309/950  (32·5%)
225/568  (39·6%)
534/1518 (35·2%)
Adjusted odds
ratio (99% CI)
0·92 (0·67–1·26)
1·35 (0·97–1·88)
0·85 (0·52–1·38)
1·08 (0·81–1·45)
1·73 (0·93–3·20)
7·43 (0·43–129·00)
0·81 (0·52–1·26)
1·20 (0·68–2·13)
1·10 (0·73–1·65)
1·73 (1·07–2·82)
1·64 (1·03–2·62)
0·73 (0·50–1·07)
1·31 (0·89–1·93)
1·17 (0·88–1·56)
1·05 (0·70–1·59)
1·21 (0·86–1·69)
1·04 (0·75–1·43)
1·36 (0·89–2·08)
1·07 (0·76–1·51)
0·91 (0·48–1·72)
1·04 (0·49–2·22)
1·13 (0·84–1·51)
0·92 (0·56–1·51)
1·39 (0·74–2·61)
1·09 (0·83–1·43)
1·20 (0·76–1·90)
1·18 (0·78–1·78)
1·09 (0·74–1·62)
1·11 (0·74–1·65)
1·32 (0·86–2·01)
1·08 (0·73–1·58)
0·97 (0·64–1·46)
1·23 (0·72–2·12)
1·16 (0·82–1·66)
1·03 (0·67–1·60)
1·02 (0·73–1·43)
1·20 (0·87–1·65)
0·91 (0·42–1·98)
1·14 (0·89–1·45)
1·10 (0·82–1·48)
1·14 (0·78–1·66)
1·12 (0·89–1·41)
0·4 1·0 3·0
Favours rt-PAFavours control
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did occur in the adjusted eﬀ ect of treatment between 
patients older than 80 years and in patients 80 years or 
younger (p=0·027), suggesting greater beneﬁ t in those 
older than 80 years of age; contrary to expectations.14 
Treatment appeared at least as eﬀ ective in this age group 
as in younger patients. Signiﬁ cant trends towards larger 
eﬀ ects of treatment in more severe strokes were also 
seen (as assessed by the NIHSS and by the predicted 
probability of a poor outcome18). Beneﬁ t was greatest in 
patients treated within 3 h, but there was insuﬃ  cient 
power to examine decay of beneﬁ t with time. An analysis 
of the treatment eﬀ ect in each of three equal-sized 
cohorts of patients (ie, those recruited in 2000–06, 
2007–08, 2009–11) did not provide any evidence of period 
eﬀ ects (data not shown). We also undertook a sensitivity 
analysis restricted to the 2939 (96%) patients with known 
6-month vital and disability status (appendix pp 4–5), and 
the results were not qualitatively diﬀ erent from those in 
table 2.
Discussion
Although the increase in the number of patients treated 
with rt-PA who were alive and independent at 6 months 
was smaller than originally anticipated and was not 
signiﬁ cant, the secondary analysis provides supportive 
evidence of beneﬁ t. The ordinal analysis provided 
evidence that on average, patients treated with intra-
venous thrombolysis up to 6 h after stroke survived with 
less disability. At 6 months, vital status was known for 
most patients and there was no evidence of any diﬀ erence 
in the number of deaths, despite the excess of deaths 
within 7 days of stroke (mainly due to intracranial 
haemorrhage). Since mortality at 6 months was equal in 
the two groups, and in view of the evidence that the lower 
the patients’ degree of disability at 6 months, the greater 
their subsequent survival,31 long-term follow-up beyond 
6 months is important. Follow-up for survival, therefore, 
continues in the UK, Norway, and Sweden to assess 
whether an overall survival advantage from rt-PA after 
6 months emerges.
Since we sought to recruit older patients and patients 
who did not strictly meet prevailing licence criteria for 
thrombolytic therapy with rt-PA, we anticipated a higher 
risk of adverse events, chieﬂ y symptomatic intracranial 
haemorrhage. The patient information leaﬂ et stated that 
rt-PA treatment might be associated with an increased 
risk of fatal intracranial haemorrhage of 4%, which 
indeed was the rate reported in the trial. Furthermore, 
applying a similar deﬁ nition of symptomatic intra-
cerebral haemorrhage as in the Cochrane systematic 
review, the frequency of this disorder within 7 days in 
IST-3 patients treated with rt-PA (6·8%) was comparable 
with the 7·3% reported in the Safe Implementation of 
Thrombolysis in Stroke (SITS) registry of 6483 patients 
treated within licence in routine clinical practice.32 We 
also expected a higher risk of death in the control group, 
and a smaller proportion alive and independent than in 
previous trials. Reassuringly, despite the diﬀ erent event 
rates in the control group, for most of the outcomes, 
there was no clear evidence that the eﬀ ects of treatment 
were qualitatively diﬀ erent in IST-3 to those seen in 
earlier randomised trials, with two exceptions. We 
identiﬁ ed signiﬁ cant trends towards larger eﬀ ects of 
treatment in patients with more severe strokes. We also 
anticipated a reduction in fatal and non-fatal neurological 
deterioration due to swelling of the initial infarct,6 so the 
clear 17 per 1000 excess was unexpected, and inconsistent 
with data from previous trials.6
As proposed by Kent and colleagues,33 we reported the 
eﬀ ect of treatment on the primary outcome in several 
prespeciﬁ ed subgroups and included the eﬀ ects sub-
divided by the result of a prognostic score. Beneﬁ t with 
treatment was greatest within 3 h, but the analyses did 
not have suﬃ  cient power to deﬁ ne the shape of the 
relation between beneﬁ t and time beyond 3 h. The eﬀ ect 
of treatment in patients older than 80 years of age was at 
least as large as in patients younger than 80 years of age. 
A formal test for trend showed a signiﬁ cant diﬀ erence 
for greater beneﬁ t of rt-PA in patients with increasingly 
severe strokes. However, in view of the overall non-
signiﬁ cant beneﬁ t for the primary outcome, the 
signiﬁ cant interactions across subgroups in these 
analyses should be interpreted with caution. As speciﬁ ed 
in the statistical analysis plan, we planned additional 
secondary analyses to explore these apparent eﬀ ects on 
the primary outcome (and on other outcomes, such as 
symptomatic intracranial haemorrhage) and to decide if 
these eﬀ ects were due to chance.
Lyden34 has identiﬁ ed limitations in these data, chieﬂ y 
that IST-3 recruited only half the number of patients 
originally intended and so was underpowered for the 
primary outcome (and more so for the subgroup 
analyses). The many changes in the regulatory envir-
onment over the course of the trial delayed the approval 
of the trial in many centres and precluded the 
participation of several countries and hence was a 
signiﬁ cant factor in our failing to achieve our original 
target.11 Nonetheless, the trial was the largest-ever trial of 
thrombolysis therapy for stroke34 (over three times larger 
than any previous trial) and included more patients 
treated within 3 h of stroke (n=849) than were included 
in the National Institute of Neurological Disorders and 
Stroke (NINDS) trial (n=624), the only previous trial 
examining speciﬁ cally treatment within 3 h (panel). The 
fact that most of the IST-3 patients treated within 3 h 
were older than 80 years of age (n=726), yet achieved 
similar beneﬁ t to younger patients in NINDS trial, adds 
to the NINDS trial.
The absence of masking is most relevant for the 
assessment of the events within 7 days. However, every 
possible precaution was taken to ensure masking of the 
expert panel assessing the scans, and the adjudication 
committee, who also assessed clinical data on all 
potential cerebral events. The proportional eﬀ ect of 
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treatment on fatal and non-fatal events within 7 days was 
very similar, which perhaps suggest that masking of 
the assessors was successful. The self-assessment at 
6 months by patients or their carer by postal question-
naire or masked telephone interview was unmasked and 
so could be subject to reporting bias.34 However, self-
reported outcome by patients is necessarily subjective 
and aﬀ ected by many things besides knowledge of 
treatment allocation. The subgroup analysis subdivided 
by trial phase provides some reassurance in that no 
signiﬁ cant diﬀ erence was seen in the eﬀ ect of treatment 
on the primary outcome in the double-blind phase and 
the open phase (ﬁ gure 3). The measurement of outcome 
with OHS at 6 months is diﬀ erent from previous trials 
that measured the modiﬁ ed Rankin score at 3 months. 
When we planned IST-3 in 1998, the modiﬁ ed Rankin 
score and OHS were judged to be equivalent. Both are 
derivatives of the original Rankin scale, developed by 
members of our group. While the proportion of patients 
recorded as dependent might be slightly diﬀ erent with 
each scale, the choice of outcome scale would not bias 
the assessment of treatment eﬀ ect between treatment 
and control groups.
The outcome was recorded at 6 months and 18 months, 
to assess the eﬀ ects on survival free of disability after a 
few months and also in the long term (the longer the 
beneﬁ t persists, the greater the cost-eﬀ ectiveness). The 
longer time to follow-up allowed any diﬀ erential eﬀ ect of 
rt-PA on early and late death to become clearer. Outcome 
(other than survival) was not recorded at 3 months, 
although the proportional eﬀ ects on death and disability 
seen at 6 months in IST-3 are comparable with those 
seen at 3 months in previous trials.
Lyden also comments that the sampling approach to 
monitoring in IST-3 was less intense than in many 
commercial studies, and is a potential concern, but also 
states: “many clinical trialists believe that source 
veriﬁ cation of some clinical trial data assures safety, 
accuracy, and validity of the trial data. Authorities do not 
agree on the minimum quantity of veriﬁ ed data to assure 
validity (100%, half, 10% sample)…but there is no 
evidence to suggest any problems with the [IST-3] data 
set due to limited monitoring.”34
When the results of IST-3 are incorporated into an 
updated systematic review,35 the estimates of relative 
treatment eﬀ ect are broadly compatible with the previous 
rt-PA trials for each of the main outcomes: alive and 
independent; death at ﬁ nal follow-up; and fatal 
intracranial haemorrhage.
Our trial was underpowered to reliably detect import ant 
subgroup eﬀ ects, and so a collaborative individual patient 
data meta-analysis (the Stroke Thrombolysis Trialists 
Collaboration [STTC]) has been established, which will 
include data from all the completed intra venous rt-PA 
trials and will update the previous pooled analysis.7 The 
meta-analysis will explore which baseline factors, other 
than time, might modify the eﬀ ects of treatment on major 
outcomes (such as death, functional outcome, and 
intracerebral haemorrhage), and so provide better 
guidance for clinicians and patients to apply this 
treatment as eﬀ ectively as possible in routine practice.
For the types of patient recruited in IST-3 (about three 
quarters of whom were randomised after 3 h, and half of 
all patients were older than 80 years of age), by 6 months 
there was evidence that rt-PA improved functional 
outcome. The data add weight to the policy of treating 
patients as soon as possible, and also justify extending 
treatment to patients older than 80 years of age. The data 
do not support any restriction of treatment on the basis 
of stroke severity or the presence of early ischaemic 
change on the baseline brain scan. The data support the 
need for randomised trials of thrombolysis in selected 
patients more than 4·5 h after stroke.
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